Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 19;11(11):CD015828.
doi: 10.1002/14651858.CD015828.

Vaccines for preventing Ebola virus disease

Rebecca Kuehn  1 , Hannah Ryan  2 , Kevin C Okwaraeke  3 , Susan Gould  4 , Marty Chaplin  1 , Matthew Riley  4 , Lance Turtle  5   6 , Shevin T Jacob  1 , Tom Fletcher  1
Affiliations

Vaccines for preventing Ebola virus disease

Rebecca Kuehn et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of vaccines to prevent Ebola virus disease in people who have been, or have potentially been, exposed to Ebola virus.

PubMed Disclaimer

Conflict of interest statement

RK has no known conflicts of interest.

HR has no known conflicts of interest. She is employed by the Liverpool University Hospitals NHS Foundation Trust.

KCO has no known conflicts of interest. KCO has worked as a clinician, managing viral haemorrhagic fevers in Nigeria.

SG has no known conflicts of interest.

MC has no known conflicts of interest. She is a Cochrane Editor and was not involved in the editorial process of this protocol.

MR has no known conflicts of interest.

LT has a share of a patent on a Zika vaccine, and is an Independent Contractor Consultant for AstraZeneca and Synairgen. Travel, accommodation, and registration (2024 only) for ECCMID 2023 and 2024 were covered by AstraZeneca.

STJ has worked as a consultant with the Clinical Unit of the World Health Organization (WHO) Health Emergencies Programme, in which capacity his roles included deployment to support the response to Filovirus disease outbreaks across sub‐Saharan Africa. He is affiliated with the Wellcome Trust (Grant/Contract) and is a WHO Independent Contractor ‐ Consultant.

TF has worked as a consultant with the Clinical Unit of the WHO Health Emergencies Programme, in which capacity his roles included deployment to support the response to global Filovirus disease outbreaks. He is a WHO Independent Contractor ‐ Consultant.

References

Additional references

Bah 2015
    1. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. New England Journal of Medicine 2015;372(1):40-7. [DOI: 10.1056/NEJMoa1411249] - DOI - PubMed
Balshem 2011
    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines. 3: rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [DOI: 10.1016/j.jclinepi.2010.07.015] - DOI - PubMed
Campbell 2020
    1. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, BrennanSE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 2020;368:l6890. [DOI: 10.1136/bmj.l6890] - DOI - PMC - PubMed
CDC 2023
    1. Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB). Ebola Disease. Available at www.cdc.gov/vhf/ebola/index.html (accessed 08 March 2024).
Coulborn 2024
    1. Coulborn RM, Bastard M, Peyraud N, Gignoux E, Luquero F, Guai B, et al. Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo. Lancet Infectious Diseases 2024;24(6):602-10. [DOI: 10.1016/S1473-3099(23)00819-8] - DOI - PubMed
Covidence [Computer program]
    1. Covidence. Melbourne, Australia: Veritas Health Innovation, 2024. Available at covidence.org.
Deeks 2023
    1. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook 2023.
Dolzhikova 2017
    1. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Human Vaccines and Immunotherapeutics 2017;13(3):613-20. [DOI: 10.1080/21645515.2016.1238535] [PMID: ] - DOI - PMC - PubMed
Eldridge 2021
    1. Eldridge S, Campbell MK, Campbell MJ, Drahota AK, Giraudeau B, Reeves BC, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2). Additional considerations for cluster-randomized trials (RoB 2 CRT). 18 March 2021. Available from www.riskofbias.info/welcome/rob-2-0-tool/rob-2-for-cluster-randomized-tr... (accessed 23 July 2024):1-22.
Elston 2017
    1. Elston JW, Cartwright C, Ndumbi P, Wright J. The health impact of the 2014-15 Ebola outbreak. Public Health 2017;143:60-70. [DOI: 10.1016/j.puhe.2016.10.020] - DOI - PubMed
EMA 2023a
    1. European Medicines Agency (EMA). Zabdeno: European public assessment reports. Available at ema.europa.eu/en/medicines/human/EPAR/zabdeno (accessed 19 September 2023).
EMA 2023b
    1. European Medicines Agency (EMA). Mvabea: European public assessment reports. Available at ema.europa.eu/en/medicines/human/EPAR/mvabea (accessed 19 September 2023).
EMA 2024
    1. European Medicines Agency (EMA). Ervebo (updated 20 February 2024). Available at www.ema.europa.eu/en/medicines/human/EPAR/ervebo (accessed 18 March 2024).
FDA 2023
    1. US Food and Drug Administration (FDA). Ervebo (updated 8 September 2023). Available at www.fda.gov/vaccines-blood-biologics/ervebo (accessed 18 March 2024).
Gao 2022
    1. Gao Y, Zhao Y, Guyatt G, Fowler R, Kojan R, Ge L, et al. Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe 2022;3(9):e683-92. [DOI: 10.1016/S2666-5247(22)00123-9] - DOI - PMC - PubMed
Goeijenbier 2014
    1. Goeijenbier M, Van Kampen J, Reusken C, Koopmans M, Van Gorp E. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Netherlands Journal of Medicine 2014;72(9):442–8. - PubMed
Higgins 2019
    1. Higgins JPT, Savović J, Page MJ, Sterne JAC (editors), on behalf of the RoB2 Development Group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Available at www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2 2019;(accessed 23 July 2024).
Higgins 2023a
    1. Higgins JP, Li T, Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from training.cochrane.org/handbook/current/chapter-06.
Higgins 2023b
    1. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from training.cochrane.org/handbook/current/chapter-08.
Lamontagne 2018
    1. Lamontagne F, Fowler RA, Adhikari NK, Murthy S, Brett-Major DM, Jacobs M, et al. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet 2018;391(10121):700-8. [DOI: 10.1016/S0140-6736(17)31795-6] - DOI - PMC - PubMed
Lefebvre 2024
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from training.cochrane.org/handbook/current/chapter-04.
Malvy 2019
    1. Malvy D, McElroy AK, Clerck H, Günther S, Griensven J. Ebola virus disease. Lancet 2019;18(393):936-48. [DOI: 10.1016/S0140-6736(18)33132-5] - DOI - PubMed
Masterson 2018
    1. Masterson SG, Lobel L, Carroll MW, Wass MN, Michaelis M. Herd immunity to ebola viruses is not a realistic target for current vaccination strategies. Frontiers in Immunology 2018;9:350333. [DOI: 10.3389/fimmu.2018.01025] - DOI - PMC - PubMed
McMahon 2016
    1. McMahon SA, Ho LS, Brown H, Miller L, Ansumana R, Kennedy CE. Healthcare providers on the frontlines: a qualitative investigation of the social and emotional impact of delivering health services during Sierra Leone's Ebola epidemic. Health Policy and Planning 2016;31(9):1232-9. [DOI: 10.1093/heapol/czw055] - DOI - PMC - PubMed
Mulangu 2019
    1. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine 2019;381(24):2293-303. [DOI: 10.1056/NEJMoa1910993] - DOI - PMC - PubMed
Page 2021
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology 2021;134:178-89. [DOI: 10.1016/j.jclinepi.2021.03.001] - DOI - PubMed
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 8.7.0. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.
Schünemann 2024
    1. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from training.cochrane.org/handbook/current/chapter-14.
Sterne 2019
    1. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898] - DOI - PubMed
Vetter 2016
    1. Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch D. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infectious Diseases 2016;16(6):e82-91. [DOI: 10.1016/ S1473-3099(16)00077-3] - PubMed
West 2014
    1. West TE, Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Annals of the American Thoracic Society 2014;11(9):1341–50. [DOI: 10.1513/AnnalsATS.201410-481PS] - DOI - PubMed
WHO 2023
    1. World Health Organization (WHO). Ebola virus disease (Factsheet). April 2023. Available from who.int/news-room/fact-sheets/detail/ebola-virus-disease (accessed 08 March 2024).
Woolsey 2021
    1. Woolsey C, Geisbert TW. Current state of Ebola virus vaccines: a snapshot. PLOS Pathogens 2021;17(12):e1010078. [DOI: 10.1371/journal.ppat.1010078] - DOI - PMC - PubMed
Zhu 2015
    1. Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015;385(9984):2272-9. [DOI: 10.1016/S0140-6736(15)60553-0] [PMID: ] - DOI - PubMed
Zhu 2017
    1. Zhu FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JB, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2017;389(10069):621-8. [DOI: 10.1016/S0140-6736(16)32617-4] - DOI - PubMed

MeSH terms

LinkOut - more resources